WallStSmart

Eyepoint Pharmaceuticals Inc (EYPT)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Eyepoint Pharmaceuticals Inc generates 926% more annual revenue ($7.61M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. EYPT earns a higher WallStSmart Score of 33/100 (F).

EYPT

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.3
Piotroski: 3/9

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EYPT2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
161.7%10/10

Revenue surging 161.7% year-over-year

Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

EYPT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.14B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EYPT

The strongest argument for EYPT centers on Revenue Growth, Debt/Equity. Revenue growth of 161.7% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : EYPT

The primary concerns for EYPT are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

EYPT profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

EYPT carries more volatility with a beta of 1.77 — expect wider price swings.

EYPT is growing revenue faster at 161.7% — sustainability is the question.

EYPT generates stronger free cash flow (-82M), providing more financial flexibility.

Bottom Line

EYPT scores higher overall (33/100 vs 24/100) and 161.7% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eyepoint Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?